

Hypothyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/H5118512EF66EN.html>

Date: September 2022

Pages: 39

Price: US\$ 2,000.00 (Single User License)

ID: H5118512EF66EN

Abstracts

Hypothyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypothyroidism - Drugs In Development, 2022, provides an overview of the Hypothyroidism (Hormonal Disorders) pipeline landscape.

Hypothyroidism (underactive thyroid) is a condition in which thyroid gland doesn't produce enough of certain important hormones. Signs and symptom include fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness and stiffness, pain and stiffness. Risk factors include autoimmune diseases, thyroid surgery, radiation therapy and family history of thyroid disease.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypothyroidism - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hypothyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypothyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypothyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 4, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hypothyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hypothyroidism (Hormonal Disorders).

The pipeline guide reviews pipeline therapeutics for Hypothyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hypothyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hypothyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hypothyroidism (Hormonal Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hypothyroidism (Hormonal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hypothyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Hypothyroidism - Overview
- Hypothyroidism - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hypothyroidism - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypothyroidism - Companies Involved in Therapeutics Development
- AbbVie Inc
- Diurnal Group Plc
- Kashiv BioSciences LLC
- Sention Therapeutics LLC
- Spectrix Therapeutics LLC
- Synthonics Inc
- Takeda Pharmaceutical Co Ltd
- Xeris Biopharma Holdings Inc
- Hypothyroidism - Drug Profiles
- (levothyroxine + liothyronine) - Drug Profile
- Product Description
- Mechanism Of Action
- (levothyroxine sodium + liothyronine sodium) - Drug Profile
- Product Description
- Mechanism Of Action
- Armour Thyroid - Drug Profile
- Product Description
- Mechanism Of Action
- levothyroxine - Drug Profile
- Product Description
- Mechanism Of Action
- liothyronine - Drug Profile

Product Description

Mechanism Of Action

liothyronine sodium SR - Drug Profile

Product Description

Mechanism Of Action

Modified Release Thyroid Hormone Formulation - Drug Profile

Product Description

Mechanism Of Action

parathyroid hormone - Drug Profile

Product Description

Mechanism Of Action

ST-1891 - Drug Profile

Product Description

Mechanism Of Action

Hypothyroidism - Dormant Projects

Hypothyroidism - Discontinued Products

Hypothyroidism - Product Development Milestones

Featured News & Press Releases

Sep 01, 2021: Xeris Pharmaceuticals completes enrollment of its phase 1 study of levothyroxine (XP-8121)

Aug 11, 2021: Xeris Pharmaceuticals announces FDA acceptance of its IND application for XeriSol Levothyroxine (XP-8121) for the treatment of hypothyroidism

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hypothyroidism, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hypothyroidism - Pipeline by AbbVie Inc, 2022
Hypothyroidism - Pipeline by Diurnal Group Plc, 2022
Hypothyroidism - Pipeline by Kashiv BioSciences LLC, 2022
Hypothyroidism - Pipeline by Sention Therapeutics LLC, 2022
Hypothyroidism - Pipeline by Spectrix Therapeutics LLC, 2022
Hypothyroidism - Pipeline by Synthomics Inc, 2022
Hypothyroidism - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Hypothyroidism - Pipeline by Xeris Biopharma Holdings Inc, 2022
Hypothyroidism - Dormant Projects, 2022
Hypothyroidism - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hypothyroidism, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Hypothyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/H5118512EF66EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H5118512EF66EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

